Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alaunos Therapeutics, Inc. (TCRT : NSDQ)

• Company Description    Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $4.93 Daily Weekly Monthly 20 Day Moving Average: 48,166 shares Shares Outstanding: 1.64 (millions) Market Capitalization: $8.09 (millions) Beta: -0.79 52 Week High: $6.80 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 64.28% 58.13% 12 Week 98.92% 67.32% Year To Date 158.97% 142.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2617 BISSONNET ST SUITE 233 - HOUSTON,TX 77005 USA ph: 346-355-4099 fax: 617-241-2855 ir@alaunos.com http://www.alaunos.com

• General Corporate Information    Officers Dale Curtis Hogue - Interim Chief Executive Officer Ferdinand Groenewald - Vice President Robert Hofmeister - Director Robert W. Postma - Director Jaime Vieser - Director Peer Information Alaunos Therapeutics, Inc. (GSAC) Alaunos Therapeutics, Inc. (CASI) Alaunos Therapeutics, Inc. (ALCD.) Alaunos Therapeutics, Inc. (OMNN) Alaunos Therapeutics, Inc. (CGPI.) Alaunos Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98973P309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 1.64 Most Recent Split Date: 7.00 (0.10:1) Beta: -0.79 Market Capitalization: $8.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 39.09% vs. Previous Quarter: -45.65% Sales Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -50.00% ROE 06/30/25 - - 03/31/25 - -169.34 12/31/24 - -140.17 ROA 06/30/25 - - 03/31/25 - -124.28 12/31/24 - -109.99 Current Ratio 06/30/25 - - 03/31/25 - 1.00 12/31/24 - 3.98 Quick Ratio 06/30/25 - - 03/31/25 - 1.00 12/31/24 - 3.98 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -40,699.99 12/31/24 - -46,790.00 Book Value 06/30/25 - - 03/31/25 - 0.66 12/31/24 - 1.29 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©